Takeda

TAKHZYRO

Manufacturer:

Takeda

Takhzyro HCPCS:

J0593

HCPCS Code Descriptor:

Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)

Category:

J Code

Takhzyro NDCs:

47783-0644-01, 47783-0646-01, 47783-0645-01

Primary Type:

Immunology

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Takhzyro:

TAKHZYRO is an Immunology drug manufactured by Takeda and administered via the Subcutaneous route of administration. The J Code: J0593 is aligned to the drug TAKHZYRO.

ACCESS PRICING AND MORE BY REGISTERING

J0593 Added Date:

October 1, 2019

J0593 Effective Date:

October 1, 2019

J0593 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Takhzyro billing and coding information.
Takhzyro patient assistance information can be found through The OnePath Co-Pay Assistance Program at the URL: https://www.takhzyro.com/copay-assistance
TAKHZYRO prescribing information can be found at the link below:
Information regarding TAKHZYRO’s side effects can be found at MedlinePlus